Funds raised from the Scottish angel investment syndicate will allow the biotech to accelerate the development of its viral vector technology for cancer treatments.
Edinburgh-based biotech company Lentitek has raised £700,000 in funding from Scottish angel investment syndicate Equity Gap. It has now raised almost £1 million over the past six months and follows a £295,000 Innovate UK grant at the end of August last year.
Funds raised will be used to accelerate the development and commercialisation of its viral vector technology for cancer treatments.
Founded in 2019, over the past six months, Lentitek says that it has gained market traction and secured evaluation agreements with several contract manufacturing companies.
Lentitek specialises in manufacturing technologies for lentiviral vectors, which are essential in the delivery of CAR-T cell and gene therapies.
“Lentitek is tackling one of the biggest challenges in modern medicine – making advanced cancer therapies more widely accessible,” said Fraser Lusty, managing director of Equity Gap.
Other life science investments from Equity Gap include Cytochroma, which provides predictive cell models from genetic backgrounds, gut ecology specialists EnteroBiotix, and Hydrosense which manufactures rapid testing kits for Legionella in water.
